Backing into Value with Part B

Teva Stands By Migraine Strategy After Ajovy Misses Boat On Express Scripts Deal

Defining access potential – Before it’s too late

Depression Rising (Again): Turning the Corner in Psychiatry’s Most Burdensome Disorder

“Manufacturers are realizing that this is going to be a feature of the landscape and some have begun to think about it as a mutual opportunity.” Steven Pearson, ICER

Harvard Pilgrim and Illumina sign first-of-its-kind value-based contract

Drug Pricing Pro Roger Longman of Real Endpoints Says Spark Therapeutics Is Making the Right Moves

Preferences in MS Therapy: White Paper and Literature Review

Smart Segmentation/ Success In The Payer-Dominated Pharma Marketplace

Contracting 2.0: The Why, When, How — And Why Not — Of Value-Based Deals